Abstract 4444
Background
Burn-Out Syndrome (BOS) in oncology nurses, has few experiences reported about its incidence and impact in its three different areas: emotional and physical exhaustion, cynism and despersonalization and no personal nor profesional fulfillment. There is a lack of resources for its diagnosis and management, although it impacts negatively in the patient attention/ care quality and the quality of institutional processes, added the personal impact in personal workers lives. Our objective was to determine the incidence of the BOS in our workers, analyze its causes and reduce in 20% the percentage of workers suffering or at risk of suffering BOS.
Methods
23 nurses / nurse assistants from Medical Oncology Department at University General Hospital of Valencia fulfilled an anomized questionnaire that included personal details, the GHQ-12 evaluation and the Maslach index questions; both at baseline and after each intervention. Causes of BOS were analysed, and process map and Ishikawa fish-bone scheme were designed. Interventions were carried in consequence. Data analyze through SPSS.
Results
23 subjects, 87% women, 47 years old median age. 15 at ward, 8 at clinic. 90% > 5 years in Oncology. At baseline, 75% GHQ-12 good health. Maslach index: 70%, 45% and 55% in risk (medium+high) of BOS related to exhaustion, despersonalization or fulfillment, respectively. In exhaustion, 35% medium risk, 35% high risk of BOS. Priority-matrix development, ergonomy tips and self-improvement tools identified as adequated interventions. After ergonomy tips intervention, 90% GHQ-12 good health, 15% exhaustion medium risk and 50% high risk; 65% at risk of BOS related to exhaustion. Improvement of 5% lowering risk of suffering BOS.
Conclusions
BOS is complex to measure due to answer subjetivity. We have healthier workers, but although levels of exhaustion have decreased, those who were already exhausted are worse than before. Possible causes: renovation work on the clinic, labor inestability, local holidays during evaluation. Self-improvement tools sessions are now being held to reduce risk ot BOS. Reevaluation of activity will be definitory of its success.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2655 - The K-BASKET trial: A prospective phase II biomarker-driven multiple basket trial in Korean solid cancer patients.
Presenter: Seul Kim
Session: Poster Display session 3
Resources:
Abstract
5938 - Cambridge Liquid biopsy “CALIBRATION” study: Can changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients with advanced oesophageal cancer receiving MEDI4736?
Presenter: Constanza Linossi
Session: Poster Display session 3
Resources:
Abstract
3799 - Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases
Presenter: Andrea Mafficini
Session: Poster Display session 3
Resources:
Abstract
4647 - Microsatellite Instability Testing and Lynch Syndrome Screening For Colorectal Cancer Patients Through Tumor Sequencing
Presenter: Li Liu
Session: Poster Display session 3
Resources:
Abstract
3231 - "Liquid Withdarw" technique in CT-guided cutting needle lung biopsy: decreased incidence of complications and increased tissue amount for lung cancer molecular testing.
Presenter: Xue Wang
Session: Poster Display session 3
Resources:
Abstract
3282 - WGS Implementation in standard cancer Diagnostics for Every cancer patient (WIDE)
Presenter: Paul Roepman
Session: Poster Display session 3
Resources:
Abstract
5905 - Known and unknown gene fusion detection capabilities of solid tumor laboratories conducting next generation sequencing in 6 countries
Presenter: Steph Finucane
Session: Poster Display session 3
Resources:
Abstract
4238 - Clinical and Analytical Accuracy of a 523 Gene Panel Next-Generation Sequencing (NGS) Assay on Formalin-Fixed Paraffin-Embedded (FFPE) Solid Tumor Samples
Presenter: Ina Deras
Session: Poster Display session 3
Resources:
Abstract
2493 - Methylation analysis of MLH1 using droplet digital PCR and methylation sensitive restriction enzyme.
Presenter: Celine De Rop
Session: Poster Display session 3
Resources:
Abstract
2963 - Analytical performance of the Resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib
Presenter: Ira Pekker
Session: Poster Display session 3
Resources:
Abstract